Get the Stockscreener App
1.57
11.30%
-0.20
After Hours:
1.58
0.01
+0.64%
Entera Bio Ltd stock is traded at $1.57, with a volume of 1.48M.
It is down -11.30% in the last 24 hours and down -26.98% over the past month.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
See More
Previous Close:
$1.77
Open:
$1.77
24h Volume:
1.48M
Relative Volume:
7.53
Market Cap:
$72.00M
Revenue:
$134.00K
Net Income/Loss:
$-9.93M
P/E Ratio:
-4.6176
EPS:
-0.34
Net Cash Flow:
$-6.72M
1W Performance:
-21.50%
1M Performance:
-26.98%
6M Performance:
-16.94%
1Y Performance:
-42.28%
1-Day Range:
$1.57
$1.81
1-Week Range:
$1.57
$1.9875
52-Week Range:
$1.5006
$3.22
Entera Bio Ltd Stock (ENTX) Company Profile
Name
Entera Bio Ltd
Sector
Industry
Phone
972-2-532-7151
Address
KIRYAT HADASSAH, MINRAV BUILDING, JERUSALEM
Compare ENTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENTX
Entera Bio Ltd
|
1.57 | 81.17M | 134.00K | -9.93M | -6.72M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Entera Bio Ltd Stock (ENTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-22-21 | Initiated | Aegis Capital | Buy |
Entera Bio Ltd Stock (ENTX) Latest News
Breakout Watch: Can Entera Bio Ltd 5DT stock surprise with quarterly results2025 Technical Overview & Low Drawdown Momentum Ideas - moha.gov.vn
Entera Bio Ltd. (NASDAQ: ENTX) director reports 2026 share and option grants - Stock Titan
Entera Bio (ENTX) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation - Yahoo! Finance Canada
Entera Bio (NASDAQ:ENTX) CEO Miranda Jayne Toledano Acquires 11,000 Shares - MarketBeat
Entera Bio Ltd. Stock (ENTX) Opinions on Insider Buying and Clinical Updates - Quiver Quantitative
ENTX Insider Trading - Quiver Quantitative
Aug Retail: What margin trends mean for Entera Bio Ltd stockPortfolio Performance Report & Daily Risk Controlled Trade Plans - moha.gov.vn
Entera Bio (NASDAQ:ENTX) Rating Increased to Sell at Wall Street Zen - MarketBeat
FY2025 EPS Estimates for Entera Bio Boosted by HC Wainwright - Defense World
HC Wainwright Increases Earnings Estimates for Entera Bio - MarketBeat
H.C. Wainwright reiterates Buy rating on Entera Bio stock as FDA qualifies BMD endpoint - Investing.com Australia
Entera Bio Congratulates the FNIH-ASBMR-SABRE Team on FDA’s Qualification of Total Hip BMD as Regulatory Endpoint: Huge Win for Osteoporosis Innovation - marketscreener.com
Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program) - Sahm
FDA clears new way to test osteoporosis drugs, aiming to cut trial time - Stock Titan
Entera Bio’s oral PTH analog shows sustained calcium response By Investing.com - Investing.com Nigeria
Entera Bio’s oral PTH analog shows sustained calcium response - Investing.com
Entera Bio Ltd. Announces Promising Preclinical Data for Once-Daily Oral PTH Treatment in Hypoparathyroidism - Quiver Quantitative
New once-a-day pill aims to replace daily injections for rare calcium disorder - Stock Titan
Entera Bio Ltd. Announces New Data Supporting Further Development of A Proprietary First-In-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program) - marketscreener.com
Can Entera Bio Ltd. stock beat analyst upgradesJuly 2025 Earnings & Safe Investment Capital Preservation Plans - Улправда
How analysts rate Entera Bio Ltd. stock todayQuarterly Portfolio Report & Advanced Technical Analysis Signals - Улправда
Can Entera Bio Ltd. stock sustain market leadership2025 Growth vs Value & Accurate Buy Signal Notifications - Улправда
Why Entera Bio Ltd. stock appeals to analystsJuly 2025 Update & Daily Volume Surge Trade Alerts - Улправда
Can Entera Bio Ltd. stock hit analyst price targets2025 Bull vs Bear & Expert Curated Trade Setups - Улправда
How Entera Bio Ltd. stock trades before earningsWeekly Investment Summary & Smart Swing Trading Alerts - Улправда
Will Entera Bio Ltd. stock remain a Wall Street favoriteJuly 2025 Market Mood & Fast Gain Stock Tips - DonanımHaber
Day Trade: Can Entera Bio Ltd. stock beat analyst upgrades2025 Key Lessons & Stepwise Trade Signal Guides - Улправда
Is Entera Bio Ltd. stock oversold or undervaluedDividend Hike & Verified Momentum Watchlists - Улправда
Chart Watch: Can Entera Bio Ltd. stock sustain market leadershipIndex Update & Verified Momentum Stock Alerts - Улправда
Pharma News: Will Entera Bio Ltd stock outperform Dow Jones indexNew Guidance & Free AI Powered Buy and Sell Recommendations - moha.gov.vn
Entera Bio (NASDAQ:ENTX) Trading Down 0.9%Here's What Happened - MarketBeat
Entera Bio Ltd. (ENTX) Drops 5% in Pre-market: No Clear Catalyst - Stocks Telegraph
Is Entera Bio Ltd. (5DT) stock dividend growth reliableJuly 2025 Intraday Action & Precise Entry and Exit Recommendations - Newser
Why Entera Bio Ltd. (5DT) stock appeals to dividend investorsQuarterly Portfolio Report & Smart Swing Trading Techniques - Newser
Will Entera Bio Ltd. (5DT) stock sustain uptrend momentumStop Loss & Long-Term Safe Investment Ideas - Newser
Will Entera Bio Ltd. (5DT) stock benefit from infrastructure billMarket Activity Summary & Capital Protection Trade Alerts - Newser
Is Entera Bio Ltd. (5DT) stock good for wealth creationEarnings Trend Report & Reliable Entry Point Trade Alerts - Newser
Can Entera Bio Ltd. (5DT) stock sustain revenue momentumWeekly Market Report & Risk Controlled Daily Trade Plans - Newser
Will Entera Bio Ltd. (5DT) stock issue positive guidanceJuly 2025 Market Mood & AI Driven Stock Price Forecasts - Newser
Will Entera Bio Ltd. (5DT) stock enhance shareholder valueJuly 2025 Spike Watch & Low Risk High Win Rate Picks - Newser
How Entera Bio Ltd. (5DT) stock expands through international marketsRate Cut & Weekly Chart Analysis and Trade Guides - Newser
Will Entera Bio Ltd. (5DT) stock hit analyst forecasts2025 Market WrapUp & Expert-Curated Trade Recommendations - Newser
Can Entera Bio Ltd. (5DT) stock expand revenue streams2025 Short Interest & High Return Trade Guides - Newser
How Entera Bio Ltd. stock performs in stagflation2025 Volatility Report & Growth Focused Entry Point Reports - Newser
Can Entera Bio Ltd. (5DT) stock surprise markets with earningsTrend Reversal & Reliable Volume Spike Alerts - Newser
Entera Bio Ltd Stock (ENTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):